Want to Help Give Away Billions? California's Stem Cell/Gene Therapy Agency Has Posted Openings

A top leader has resigned, two other significant openings

Abla Creasey, CIRM’s rare disease leader — CIRM photo

A key leader at the $12 billion California stem cell and gene therapy agency has resigned, leaving a void in its effort to develop a platform technology program to stimulate treatments for rare diseases.

She is Abla Creasey, formerly executive strategy officer, rare disease, at the California Institute for Regenerative Medicine (CIRM), as the agency is formally known. Creasey was the moving force behind the agency’s new priority for a rare disease platform. She reported directly to the CIRM CEO and president.

Last year, she noted the major presence of rare disease research in the CIRM portfolio, “Fifty percent of our portfolio is in rare diseases, which is an impressive number.”

Creasey told the California Stem Cell Report